Literature DB >> 31949940

Diagnostic and management strategies for lateral pelvic lymph nodes in low rectal cancer-a review of the evidence.

Dedrick Kok Hong Chan1,2, Ker-Kan Tan1,2, Takashi Akiyoshi3.   

Abstract

Patients with low rectal cancer who have enlarged lateral pelvic lymph nodes are known to have a worse prognosis. There is however uncertainty over what constitutes a lateral pelvic lymph node of clinical significance. As the main modality for the detection of such lymph nodes is magnetic resonance imaging (MRI), characteristics of these lateral lymph nodes identified may have prognostic value and assist with guiding treatment. Options to manage such lateral lymph nodes includes neoadjuvant chemoradiotherapy as well as lateral lymph node dissection. Surgery is extensive and may lead to significant morbidity to the patient. This review article evaluates diagnostic and management strategies in patients with lateral pelvic lymph nodes in low rectal cancer. 2019 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Lateral pelvic lymph node; lateral pelvic lymph node dissection; low rectal cancer; neoadjuvant chemoradiotherapy

Year:  2019        PMID: 31949940      PMCID: PMC6955001          DOI: 10.21037/jgo.2019.01.22

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  36 in total

1.  Is lateral pelvic lymph node dissection no longer necessary for low rectal cancer after neoadjuvant therapy and TME to reduce local recurrence?

Authors:  Takashi Akiyoshi; Toshiaki Watanabe; Masashi Ueno
Journal:  J Gastrointest Surg       Date:  2012-07-06       Impact factor: 3.452

2.  Lateral pelvic lymph node dissection or chemoradiotherapy: which is the procedure of choice to reduce local recurrence rate in lower rectal cancer?

Authors:  Toshiaki Watanabe; Keiji Matsuda; Keijiro Nozawa; Takashi Kobunai
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

3.  Pelvic autonomic nerve preservation for patients with rectal carcinoma. Oncologic and functional outcome.

Authors:  K Sugihara; Y Moriya; T Akasu; S Fujita
Journal:  Cancer       Date:  1996-11-01       Impact factor: 6.860

4.  Impact of Lateral Pelvic Lymph Node Dissection on the Survival of Patients with T3 and T4 Low Rectal Cancer.

Authors:  Heita Ozawa; Kenjiro Kotake; Miki Hosaka; Akira Hirata; Kenichi Sugihara
Journal:  World J Surg       Date:  2016-06       Impact factor: 3.352

5.  The important risk factor for lateral pelvic lymph node metastasis of lower rectal cancer is node-positive status on magnetic resonance imaging: study of the Lymph Node Committee of Japanese Society for Cancer of the Colon and Rectum.

Authors:  Shimpei Ogawa; Jin-Ichi Hida; Hideyuki Ike; Tetsushi Kinugasa; Mitsuyoshi Ota; Eiji Shinto; Michio Itabashi; Takahiro Okamoto; Kenichi Sugihara
Journal:  Int J Colorectal Dis       Date:  2016-08-30       Impact factor: 2.571

6.  Indications for Lateral Pelvic Lymph Node Dissection Based on Magnetic Resonance Imaging Before and After Preoperative Chemoradiotherapy in Patients with Advanced Low-Rectal Cancer.

Authors:  Takashi Akiyoshi; Kiyoshi Matsueda; Makiko Hiratsuka; Toshiyuki Unno; Jun Nagata; Toshiya Nagasaki; Tsuyoshi Konishi; Yoshiya Fujimoto; Satoshi Nagayama; Yosuke Fukunaga; Masashi Ueno
Journal:  Ann Surg Oncol       Date:  2015-04-21       Impact factor: 5.344

7.  Male sexual dysfunction after rectal cancer surgery: Results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212.

Authors:  S Saito; S Fujita; J Mizusawa; Y Kanemitsu; N Saito; Y Kinugasa; Y Akazai; M Ota; M Ohue; K Komori; M Shiozawa; T Yamaguchi; T Akasu; Y Moriya
Journal:  Eur J Surg Oncol       Date:  2016-07-30       Impact factor: 4.424

8.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Soichiro Ishihara; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Narikazu Boku; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2015-03-18       Impact factor: 3.402

9.  Utility of the sentinel node concept for detection of lateral pelvic lymph node metastasis in lower rectal cancer.

Authors:  Shigehiro Yanagita; Yoshikazu Uenosono; Takaaki Arigami; Yoshiaki Kita; Shinichiro Mori; Shoji Natsugoe
Journal:  BMC Cancer       Date:  2017-06-19       Impact factor: 4.430

10.  Prediction of lateral pelvic lymph node metastasis in patients with locally advanced rectal cancer with preoperative chemoradiotherapy: Focus on MR imaging findings.

Authors:  Min Ju Kim; Bo Yun Hur; Eun Sun Lee; Boram Park; Jungnam Joo; Min Jung Kim; Sung Chan Park; Ji Yeon Baek; Hee Jin Chang; Dae Yong Kim; Jae Hwan Oh
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

View more
  2 in total

1.  ASO Author Reflections: CT-Based Radiomics Model to Predict Lateral Lymph Node Metastasis After Neoadjuvant (Chemo)Radiotherapy in Advanced Low Rectal Cancer.

Authors:  Ryota Nakanishi; Takashi Akiyoshi
Journal:  Ann Surg Oncol       Date:  2020-08-01       Impact factor: 5.344

Review 2.  Rise and fall of total mesorectal excision with lateral pelvic lymphadenectomy for rectal cancer: an updated systematic review and meta-analysis of 11,366 patients.

Authors:  Gabriele Anania; Richard Justin Davies; Alberto Arezzo; Francesco Bagolini; Vito D'Andrea; Luigina Graziosi; Salomone Di Saverio; Georgi Popivanov; Isaac Cheruiyot; Roberto Cirocchi; Annibale Donini
Journal:  Int J Colorectal Dis       Date:  2021-06-14       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.